ABIVAX Société Anonyme (ABVX)
Develops immune-regulating drugs to treat inflammatory bowel diseases like Crohn's and ulcerative colitis.
$124.83-0.02%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+73.5%
The outlook
ABVX is trading above both its 50- and 200-day moving averages, sitting roughly 71% of the way through its 52-week range. Analyst consensus is Strong Buy, with an average price target about 33% above the current price. The stock shows strength by technical positioning and analyst sentiment, though it remains flat today.
What’s behind the score
Analyst consensusStrong Buy — 1.4 avg of 11 analysts
Price trendAbove its 50- & 200-day averages
52-week range71% of the way from its 52-week low to high
Price targetAvg target +33% vs current price
Analyst price target
~12-month · 11 analysts$165.91average target+32.9% vs now
Now $124.83
Low $142.00High $187.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$10.88B
52-wk high
$148.83
52-wk low
$66.11
50-day avg
$117.95
200-day avg
$116.21
Trailing P/E
—